Medicenna Therapeutics Corp's shares have seen significant declines this week, with a notable drop on Wednesday.
This week, Medicenna Therapeutics Corp (MDNA.TO) has experienced a challenging period in the market, marked by a sharp decline in share price. As of Wednesday, the stock was down 4.76% for the day and 13.04% for the week, reflecting ongoing volatility in the healthcare sector.
Investor takeaway: Investors in Medicenna should remain cautious as the stock continues to be affected by broader market trends and company-specific developments. The recent public offering and participation in industry conferences may provide some optimism, but the significant drop in share price this year underscores the need for careful consideration.
Advertisement
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeMarket cap
$36.92M
52W high
$1.97
52W low
$0.34
1W change
-13.04%
Beta
1.96
Analyst Price Targets
Based on analyst covering MDNA
Wall Street analysts forecast MDNA stock price to rise 700.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+700.0% Upside
Current Price
C$0.40
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
67.3%
Annualized
90-Day Vol
65.8%
Annualized
Trend (90d)
-30.4%
Annualized drift
90d Mean
C$0.36
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.39 | C$0.31 – C$0.49 |
| 60 trading days | C$0.37 | C$0.27 – C$0.52 |
| 90 trading days | C$0.36 | C$0.24 – C$0.54 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
C$0.39 Close with 60% Year-to-Date Decline
The stock's closing price of C$0.39 is a stark contrast to its 52-week high of C$1.97, highlighting the challenges Medicenna faces in regaining investor confidence.
Bull case
Analysts are optimistic about Medicenna, with an average price target of C$3.20, suggesting a potential upside of over 700%. The company’s advancements in its IL-2, IL-4, and IL-13 Superkine platforms, along with strong patent protection, could enhance its market position and drive future growth.
Bear case
However, the stock has dropped 60% year-to-date, indicating significant investor concern. The lack of immediate positive catalysts and ongoing financial losses may weigh heavily on the stock's recovery in the near term.
Recent Price Action
Medicenna Therapeutics Corp's stock closed at C$0.39 on Wednesday, reflecting a 4.76% decline for the day and a significant drop of 13.04% over the week. The year-to-date performance shows a troubling decline of 60%, indicating a challenging market environment for the company.
Company News and Developments
Advertisement
Despite the downturn, Medicenna has made headlines recently with its participation in the H.C. Wainwright 28th Annual Global Investment Conference. Additionally, the company reported its first-quarter fiscal 2027 financial results and highlighted operational achievements in its fiscal year 2026 report. These developments may signal ongoing efforts to enhance its market presence and investor appeal.
Technical Picture
From a technical perspective, Medicenna's stock is currently trading just below its 50-day moving average of C$0.40, indicating a bearish trend. The 200-day moving average stands at C$0.68, suggesting a significant gap that reflects the stock's struggles. The 52-week range of C$0.34 – C$1.97 indicates that the stock is currently near the lower end of this range. The beta of 1.96 suggests higher volatility compared to the broader market.
Volume Insights
The latest trading volume for Medicenna was 75,684 shares, which is slightly above its 20-day average volume of 47,572 shares. This indicates a moderate level of trading activity, suggesting that investors are closely monitoring the stock amid recent developments.
Price Action Summary
In summary, Medicenna Therapeutics Corp closed at C$0.39, reflecting a 4.76% decline for the day. The stock's performance over the past week and year underscores the challenges faced by the company, as it continues to navigate a volatile market landscape.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
